POSTERS ASCO 2024

Cáncer de mama

Metastásico

First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.

First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.

Abstract: 1023 Poster Bd #: 1

Poster

Descargar

Autor
Cristina Saura, MD, PhD

Vall d’Hebron University Hospital, Vall d'Hebron Institute of Oncology

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON